Kylie Lange
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kylie Lange has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Michael Horowitz
Adelaide Medical School, University of Adelaide, Adelaide, Australia
12 shared publications - Ian McPhee Chapman
Department of Medicine, University of Adelaide, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia
10 shared publications - Stijn Soenen
Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Royal Adelaide Hospital, Adelaide, SA 5000, Australia
9 shared publications - Karen Louise Jones
School of Medicine, College of Health Adelaide University Adelaide Australia
8 shared publications - Caroline Giezenaar
Food Experience and Sensory Testing (Feast) Lab, School of Food and Advanced Technology, Massey University, Palmerston North 4410, New Zealand
7 shared publications - Lee-Anne Chapple
Adelaide Medical School, University of Adelaide, Adelaide, Australia; Intensive Care Research Unit, Royal Adelaide Hospital, Adelaide, Australia
6 shared publications
Latest Publications
- Open Access
Reduced dietary protein intake does not alter autophagy in human blood: a randomized crossover study in healthy adults
Background & aims: Autophagy activation is a promising strategy to counteract age-related cellular dysfunction. While preclinical studies suggest dietary protein restriction can induce autophagy via mTORC1 inhibition, direct human evidence using dynamic, flux-based measurements remains limited. The aim of this study was to determine whether a low protein diet could modulate autophagic flux in humans. Methods: We conducted a randomized crossover trial in which 74 healthy adults were randomized to receive two 4-week interventions of either average-protein (20% energy) or reduced-protein (10% energy) diets prescribed to maintain calculated energy balance, separated by a 4-week washout period. The primary outcome was autophagic flux measured in whole blood using a validated assay that preserves PBMCs in their physiological environment during lysosomal inhibition. Secondary outcomes included metabolic markers, body composition, and self-reported health metrics. Results: Sixty-three participants completed both interventions (mean ± SD age 29.5 ± 7.2 yrs; BMI 24.0 ± 3.2 kg/m 2 ). Reducing protein intake did not alter autophagic flux (adjusted mean difference: −8.46 ng LC3B-II/mg protein/h; 95% CI: −24.06 to 7.14; p = 0.28). Metabolomic profiling confirmed effective dietary separation, with lower circulating urea following reduced protein intake. Small differences in body weight and muscle mass were observed, while fat mass was unaffected. Fasting glucose, insulin, lipids, blood pressure, and quality of life did not differ between the two diets. Conclusions: Moderate protein restriction does not increase basal autophagy in circulating immune cells of healthy adults, suggesting protein reduction alone, without caloric deficit, may be insufficient to activate autophagy in human blood. Clinical trial registry number: Australian New Zealand Clinical Trials Registry Identifier ACTRN12623000260628 https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382790
Open AccessReduced dietary protein intake does not alter autophagy in human blood: a randomized crossover study in healthy adults
Background & aims: Autophagy activation is a promising strategy to counteract age-related cellular dysfunction. While preclinical studies suggest dietary protein restriction can induce autophagy via mTORC1 inhibition, direct human evidence using dynamic, flux-based measurements remains limited. The aim of this study was to determine whether a low protein diet could modulate autophagic flux in humans. Methods: We conducted a randomized crossover trial in which 74 healthy adults were randomized to receive two 4-week interventions of either average-protein (20% energy) or reduced-protein (10% energy) diets prescribed to maintain calculated energy balance, separated by a 4-week washout period. The primary outcome was autophagic flux measured in whole blood using a validated assay that preserves PBMCs in their physiological environment during lysosomal inhibition. Secondary outcomes included metabolic markers, body composition, and self-reported health metrics. Results: Sixty-three participants completed both interventions (mean ± SD age 29.5 ± 7.2 yrs; BMI 24.0 ± 3.2 kg/m 2 ). Reducing protein intake did not alter autophagic flux (adjusted mean difference: −8.46 ng LC3B-II/mg protein/h; 95% CI: −24.06 to 7.14; p = 0.28). Metabolomic profiling confirmed effective dietary separation, with lower circulating urea following reduced protein intake. Small differences in body weight and muscle mass were observed, while fat mass was unaffected. Fasting glucose, insulin, lipids, blood pressure, and quality of life did not differ between the two diets. Conclusions: Moderate protein restriction does not increase basal autophagy in circulating immune cells of healthy adults, suggesting protein reduction alone, without caloric deficit, may be insufficient to activate autophagy in human blood. Clinical trial registry number: Australian New Zealand Clinical Trials Registry Identifier ACTRN12623000260628 https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382790
- Top Cited PapersOpen Access
- 24 February 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (5) , 964-971
Increasing protein dose does not further augment muscle protein synthesis in critical illness: a randomized, controlled clinical trial
Rationale: Critical illness impairs the muscle protein synthetic response to protein administration. Whether increased protein dose can overcome this anabolic resistance is unknown. Objectives: To assess the impact of a single intraduodenal bolus of 40 g protein compared to 20 g of protein in mechanically ventilated critically ill patients on the primary outcome of postprandial muscle protein synthesis rates. Methods: Mechanically ventilated patients were randomized to 40 or 20 g of whey protein isolate delivered intraduodenally over 1 h. Primed continuous intravenous L-[ring-13C6]-phenylalanine and L-[3,5-2H2]-tyrosine infusions were applied with repeated arterial blood and skeletal muscle tissue sampling over 2 h fasting and 6 h postprandial periods to assess plasma amino acid responses and rates of fasting and postprandial muscle protein synthesis (primary outcome). Data are mean ± SD and area under the curve (AUC), analyzed with ANCOVA adjusted for fasting rate and paired t-tests (P < .05). Measurements and main results: Twenty patients (n = 10/group: 40 g: 90% male, 49 ± 21 y and 20 g: 80% male, 51 ± 13 y) were studied. Postprandial muscle protein synthesis rates (primary outcome) did not differ between groups (40 g vs 20 g: 0.030 ± 0.012 vs 0.025 ± 0.010%·h−1; adjusted mean difference 0.007 (95% CI, −0.003 to 0.016) %·h−1; P = .152). Postprandial plasma leucine and tyrosine availability (AUC) were higher following 40 g vs 20 g protein (leucine: 263 ± 87 vs 194 ± 54 µmol·L−1, P = .005; tyrosine: 92 ± 24 vs 63 ± 17 µmol·L−1, P = .006). Fasting muscle protein synthesis rates did not differ between groups (40 g vs 20 g: 0.020 ± 0.012 vs 0.025 ± 0.023%·h−1; P = .558). The post hoc uncontrolled analysis of muscle protein synthesis rates from fasting to postprandial periods increased in the 40 g group only (P = .005). Conclusion: Higher enteral protein does not further augment postprandial muscle protein synthesis rates to overcome anabolic resistance during critical illness, despite increased plasma amino acid availability. Trial Registration Number: Australia New Zealand Clinical Trials Registry Identifier: ACTRN12620000776909.
- 24 February 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 212 (5) , 964-971
Top Cited PapersOpen AccessIncreasing protein dose does not further augment muscle protein synthesis in critical illness: a randomized, controlled clinical trial
Rationale: Critical illness impairs the muscle protein synthetic response to protein administration. Whether increased protein dose can overcome this anabolic resistance is unknown. Objectives: To assess the impact of a single intraduodenal bolus of 40 g protein compared to 20 g of protein in mechanically ventilated critically ill patients on the primary outcome of postprandial muscle protein synthesis rates. Methods: Mechanically ventilated patients were randomized to 40 or 20 g of whey protein isolate delivered intraduodenally over 1 h. Primed continuous intravenous L-[ring-13C6]-phenylalanine and L-[3,5-2H2]-tyrosine infusions were applied with repeated arterial blood and skeletal muscle tissue sampling over 2 h fasting and 6 h postprandial periods to assess plasma amino acid responses and rates of fasting and postprandial muscle protein synthesis (primary outcome). Data are mean ± SD and area under the curve (AUC), analyzed with ANCOVA adjusted for fasting rate and paired t-tests (P < .05). Measurements and main results: Twenty patients (n = 10/group: 40 g: 90% male, 49 ± 21 y and 20 g: 80% male, 51 ± 13 y) were studied. Postprandial muscle protein synthesis rates (primary outcome) did not differ between groups (40 g vs 20 g: 0.030 ± 0.012 vs 0.025 ± 0.010%·h−1; adjusted mean difference 0.007 (95% CI, −0.003 to 0.016) %·h−1; P = .152). Postprandial plasma leucine and tyrosine availability (AUC) were higher following 40 g vs 20 g protein (leucine: 263 ± 87 vs 194 ± 54 µmol·L−1, P = .005; tyrosine: 92 ± 24 vs 63 ± 17 µmol·L−1, P = .006). Fasting muscle protein synthesis rates did not differ between groups (40 g vs 20 g: 0.020 ± 0.012 vs 0.025 ± 0.023%·h−1; P = .558). The post hoc uncontrolled analysis of muscle protein synthesis rates from fasting to postprandial periods increased in the 40 g group only (P = .005). Conclusion: Higher enteral protein does not further augment postprandial muscle protein synthesis rates to overcome anabolic resistance during critical illness, despite increased plasma amino acid availability. Trial Registration Number: Australia New Zealand Clinical Trials Registry Identifier: ACTRN12620000776909.
- Open Access
- 30 January 2026
- Published by SAGE Publications in Clinical Trials
- Vol. 23 (2) , 225-231
An online sample size calculator for designing partially clustered trials
Background: Partially clustered trials are trials that, by design, include a mixture of independent and clustered observations. For example, neonatal trials may include infants from a single, twin or triplet birth. The clustering of observations in partially clustered trials should be accounted for when determining the target sample size to avoid treatment arm comparisons being over or under powered. Limited tools are currently available for calculating the sample size for partially clustered trials, particularly when the maximum cluster size is greater than 2. The aim of this article is to introduce a new online application to calculate the target sample size for partially clustered trials covering a broad range of scenarios. Methods: The target sample size is calculated using design effects recently derived for two-arm partially clustered trials when the clusters exist prior to randomisation and the outcome of interest is continuous or binary. Both cluster and individual randomisation are considered for the clustered observations (resulting in nested and crossed designs, respectively). The sample size depends on quantities needed for typical sample size calculations, such as the effect size of interest, and the desired significance level and power. In addition, the sample size for partially clustered trials also depends on the range of cluster sizes, the proportion of observations that belong to clusters of each size, the intracluster correlation coefficient, the method of randomisation for the clustered observations, and the model that will be used for analysis. We developed an R Shiny web application that implements these methods in an easy-to-use sample size calculator that is freely available online. Results: The sample size calculator is free to access and provides trialists with the ability to determine the target sample size for different types of partially clustered trials. Step-by-step instructions are provided to illustrate the use of the calculator for designing two hypothetical trials. The target sample size that accounts for partial clustering can be quite different to the sample size that is calculated by methods for an independent design that ignore the clustering. Conclusion: Partial clustering affects the power and sample size requirements of clinical trials. The calculator presented in this article allows trialists to account for the clustering that occurs in two-arm partially clustered trials for binary and continuous outcomes and ensure their trials are appropriately powered.
- 30 January 2026
- Published by SAGE Publications in Clinical Trials
- Vol. 23 (2) , 225-231
Open AccessAn online sample size calculator for designing partially clustered trials
Background: Partially clustered trials are trials that, by design, include a mixture of independent and clustered observations. For example, neonatal trials may include infants from a single, twin or triplet birth. The clustering of observations in partially clustered trials should be accounted for when determining the target sample size to avoid treatment arm comparisons being over or under powered. Limited tools are currently available for calculating the sample size for partially clustered trials, particularly when the maximum cluster size is greater than 2. The aim of this article is to introduce a new online application to calculate the target sample size for partially clustered trials covering a broad range of scenarios. Methods: The target sample size is calculated using design effects recently derived for two-arm partially clustered trials when the clusters exist prior to randomisation and the outcome of interest is continuous or binary. Both cluster and individual randomisation are considered for the clustered observations (resulting in nested and crossed designs, respectively). The sample size depends on quantities needed for typical sample size calculations, such as the effect size of interest, and the desired significance level and power. In addition, the sample size for partially clustered trials also depends on the range of cluster sizes, the proportion of observations that belong to clusters of each size, the intracluster correlation coefficient, the method of randomisation for the clustered observations, and the model that will be used for analysis. We developed an R Shiny web application that implements these methods in an easy-to-use sample size calculator that is freely available online. Results: The sample size calculator is free to access and provides trialists with the ability to determine the target sample size for different types of partially clustered trials. Step-by-step instructions are provided to illustrate the use of the calculator for designing two hypothetical trials. The target sample size that accounts for partial clustering can be quite different to the sample size that is calculated by methods for an independent design that ignore the clustering. Conclusion: Partial clustering affects the power and sample size requirements of clinical trials. The calculator presented in this article allows trialists to account for the clustering that occurs in two-arm partially clustered trials for binary and continuous outcomes and ensure their trials are appropriately powered.
- Open Access
- 15 July 2025
- Published by Wiley in Statistics in Medicine
- Vol. 44 (15-17) , e70172
Sample Size Calculations for Partially Clustered Trials
Partially clustered trials are defined as trials where some observations belong to a cluster and others are independent. For example, neonatal trials may include infants from a single, twin, or triplet birth. The clustering of observations in partially clustered trials should be accounted for when determining the target sample size to avoid being over or underpowered. However, sample size methods have only been developed for limited partially clustered trial designs (e.g., designs with maximum cluster sizes of 2). In this article, we present new design effects that can be used to determine the sample size for two‐arm, parallel, partially clustered trials where clusters exist pre‐randomization. Design effects are derived algebraically for continuous and binary outcomes, assuming a generalized estimating equations‐based approach to estimation with either an independence or exchangeable working correlation structure. Both cluster and individual randomization are considered for the clustered observations. The design effects are shown to depend on the intracluster correlation coefficient, proportion of observations that belong to clusters of each size, method of randomization, type of outcome, and working correlation structure. The design effects are validated through a simulation study. Example sample size calculations are presented to illustrate how the design effects can be used to determine the target sample size for different partially clustered trial designs. The design effects depend on parameters that can be feasibly estimated when planning a trial and can be used to ensure that partially clustered trials are appropriately powered in the future.
- 15 July 2025
- Published by Wiley in Statistics in Medicine
- Vol. 44 (15-17) , e70172
Open AccessSample Size Calculations for Partially Clustered Trials
Partially clustered trials are defined as trials where some observations belong to a cluster and others are independent. For example, neonatal trials may include infants from a single, twin, or triplet birth. The clustering of observations in partially clustered trials should be accounted for when determining the target sample size to avoid being over or underpowered. However, sample size methods have only been developed for limited partially clustered trial designs (e.g., designs with maximum cluster sizes of 2). In this article, we present new design effects that can be used to determine the sample size for two‐arm, parallel, partially clustered trials where clusters exist pre‐randomization. Design effects are derived algebraically for continuous and binary outcomes, assuming a generalized estimating equations‐based approach to estimation with either an independence or exchangeable working correlation structure. Both cluster and individual randomization are considered for the clustered observations. The design effects are shown to depend on the intracluster correlation coefficient, proportion of observations that belong to clusters of each size, method of randomization, type of outcome, and working correlation structure. The design effects are validated through a simulation study. Example sample size calculations are presented to illustrate how the design effects can be used to determine the target sample size for different partially clustered trial designs. The design effects depend on parameters that can be feasibly estimated when planning a trial and can be used to ensure that partially clustered trials are appropriately powered in the future.
- Open Access
- 4 September 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (25) , 4819-4835
Performance of mixed effects models and generalized estimating equations for continuous outcomes in partially clustered trials including both independent and paired data
Many clinical trials involve partially clustered data, where some observations belong to a cluster and others can be considered independent. For example, neonatal trials may include infants from single or multiple births. Sample size and analysis methods for these trials have received limited attention. A simulation study was conducted to (1) assess whether existing power formulas based on generalized estimating equations (GEEs) provide an adequate approximation to the power achieved by mixed effects models, and (2) compare the performance of mixed models vs GEEs in estimating the effect of treatment on a continuous outcome. We considered clusters that exist prior to randomization with a maximum cluster size of 2, three methods of randomizing the clustered observations, and simulated datasets with uninformative cluster size and the sample size required to achieve 80% power according to GEE‐based formulas with an independence or exchangeable working correlation structure. The empirical power of the mixed model approach was close to the nominal level when sample size was calculated using the exchangeable GEE formula, but was often too high when the sample size was based on the independence GEE formula. The independence GEE always converged and performed well in all scenarios. Performance of the exchangeable GEE and mixed model was also acceptable under cluster randomization, though under‐coverage and inflated type I error rates could occur with other methods of randomization. Analysis of partially clustered trials using GEEs with an independence working correlation structure may be preferred to avoid the limitations of mixed models and exchangeable GEEs.
- 4 September 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (25) , 4819-4835
Open AccessPerformance of mixed effects models and generalized estimating equations for continuous outcomes in partially clustered trials including both independent and paired data
Many clinical trials involve partially clustered data, where some observations belong to a cluster and others can be considered independent. For example, neonatal trials may include infants from single or multiple births. Sample size and analysis methods for these trials have received limited attention. A simulation study was conducted to (1) assess whether existing power formulas based on generalized estimating equations (GEEs) provide an adequate approximation to the power achieved by mixed effects models, and (2) compare the performance of mixed models vs GEEs in estimating the effect of treatment on a continuous outcome. We considered clusters that exist prior to randomization with a maximum cluster size of 2, three methods of randomizing the clustered observations, and simulated datasets with uninformative cluster size and the sample size required to achieve 80% power according to GEE‐based formulas with an independence or exchangeable working correlation structure. The empirical power of the mixed model approach was close to the nominal level when sample size was calculated using the exchangeable GEE formula, but was often too high when the sample size was based on the independence GEE formula. The independence GEE always converged and performed well in all scenarios. Performance of the exchangeable GEE and mixed model was also acceptable under cluster randomization, though under‐coverage and inflated type I error rates could occur with other methods of randomization. Analysis of partially clustered trials using GEEs with an independence working correlation structure may be preferred to avoid the limitations of mixed models and exchangeable GEEs.
- Open Access
- 22 August 2024
- Published by Elsevier in Australian Critical Care
- Vol. 38 (1) , 101097
Nutrition intake, muscle thickness, and recovery outcomes for critically ill patients requiring non-invasive forms of respiratory support: A prospective observational study
- 22 August 2024
- Published by Elsevier in Australian Critical Care
- Vol. 38 (1) , 101097
Open AccessNutrition intake, muscle thickness, and recovery outcomes for critically ill patients requiring non-invasive forms of respiratory support: A prospective observational study
- Open Access
Effects of Quinine on the Glycaemic Response to, and Gastric Emptying of, a Mixed-Nutrient Drink in Females and Males
Intraduodenal quinine, in the dose of 600 mg, stimulates glucagon-like peptide-1 (GLP-1), cholecystokinin and insulin; slows gastric emptying (GE); and lowers post-meal glucose in men. Oral sensitivity to bitter substances may be greater in women than men. We, accordingly, evaluated the dose-related effects of quinine on GE, and the glycaemic responses to, a mixed-nutrient drink in females, and compared the effects of the higher dose with those in males. A total of 13 female and 13 male healthy volunteers received quinine-hydrochloride (600 mg (‘QHCl-600’) or 300 mg (‘QHCl-300’, females only) or control (‘C’), intraduodenally (10 mL bolus) 30 min before a drink (500 kcal, 74 g carbohydrates). Plasma glucose, insulin, C-peptide, GLP-1, glucose-dependent insulinotropic polypeptide (GIP) and cholecystokinin were measured at baseline, for 30 min after quinine alone, and then for 2 h post-drink. GE was measured by 13C-acetate breath-test. QHCl-600 alone stimulated insulin, C-peptide and GLP-1 secretion compared to C. Post-drink, QHCl-600 reduced plasma glucose, stimulated C-peptide and GLP-1, and increased the C-peptide/glucose ratio and oral disposition index, while cholecystokinin and GIP were less, in females and males. QHCl-600 also slowed GE compared to C in males and compared to QHCl-300 in females (p < 0.05). QHCl-300 reduced post-meal glucose concentrations and increased the C-peptide/glucose ratio, compared to C (p < 0.05). Magnitudes of glucose lowering and increase in C-peptide/glucose ratio by QHCl-600 were greater in females than males (p < 0.05). We conclude that quinine modulates glucoregulatory functions, associated with glucose lowering in healthy males and females. However, glucose lowering appears to be greater in females than males, without apparent differential effects on GI functions.
Open AccessEffects of Quinine on the Glycaemic Response to, and Gastric Emptying of, a Mixed-Nutrient Drink in Females and Males
Intraduodenal quinine, in the dose of 600 mg, stimulates glucagon-like peptide-1 (GLP-1), cholecystokinin and insulin; slows gastric emptying (GE); and lowers post-meal glucose in men. Oral sensitivity to bitter substances may be greater in women than men. We, accordingly, evaluated the dose-related effects of quinine on GE, and the glycaemic responses to, a mixed-nutrient drink in females, and compared the effects of the higher dose with those in males. A total of 13 female and 13 male healthy volunteers received quinine-hydrochloride (600 mg (‘QHCl-600’) or 300 mg (‘QHCl-300’, females only) or control (‘C’), intraduodenally (10 mL bolus) 30 min before a drink (500 kcal, 74 g carbohydrates). Plasma glucose, insulin, C-peptide, GLP-1, glucose-dependent insulinotropic polypeptide (GIP) and cholecystokinin were measured at baseline, for 30 min after quinine alone, and then for 2 h post-drink. GE was measured by 13C-acetate breath-test. QHCl-600 alone stimulated insulin, C-peptide and GLP-1 secretion compared to C. Post-drink, QHCl-600 reduced plasma glucose, stimulated C-peptide and GLP-1, and increased the C-peptide/glucose ratio and oral disposition index, while cholecystokinin and GIP were less, in females and males. QHCl-600 also slowed GE compared to C in males and compared to QHCl-300 in females (p < 0.05). QHCl-300 reduced post-meal glucose concentrations and increased the C-peptide/glucose ratio, compared to C (p < 0.05). Magnitudes of glucose lowering and increase in C-peptide/glucose ratio by QHCl-600 were greater in females than males (p < 0.05). We conclude that quinine modulates glucoregulatory functions, associated with glucose lowering in healthy males and females. However, glucose lowering appears to be greater in females than males, without apparent differential effects on GI functions.
- Open Access
- 10 January 2023
- Published by SAGE Publications in Clinical Trials
- Vol. 20 (2) , 99-110
Partially clustered designs for clinical trials: Unifying existing designs using consistent terminology
Introduction: Clinical trial designs based on the assumption of independent observations are well established. Clustered clinical trial designs, where all observational units belong to a cluster and outcomes within clusters are expected to be correlated, have also received considerable attention. However, many clinical trials involve partially clustered data, where only some observational units belong to a cluster. Examples of such trials occur in neonatology, where participants include infants from both singleton and multiple births, and ophthalmology, where one or two eyes per participant may need treatment. Partial clustering can also arise in trials of group-based treatments (e.g. group education or counselling sessions) or treatments administered individually by a discrete number of health care professionals (e.g. surgeons or physical therapists), when this is compared to an unclustered control arm. Trials involving partially clustered data have received limited attention in the literature and the current lack of standardised terminology may be hampering the development and dissemination of methods for designing and analysing these trials. Methods and examples: In this article, we present an overarching definition of partially clustered trials, bringing together several existing trial designs including those for group-based treatments, clustering due to facilitator effects and the re-randomisation design. We define and describe four types of partially clustered trial designs, characterised by whether the clustering occurs pre-randomisation or post-randomisation and, in the case of pre-randomisation clustering, by the method of randomisation that is used for the clustered observations (individual randomisation, cluster randomisation or balanced randomisation within clusters). Real life examples are provided to highlight the occurrence of partially clustered trials across a variety of fields. To assess how partially clustered trials are currently reported, we review published reports of partially clustered trials. Discussion: Our findings demonstrate that the description of these trials is often incomplete and the terminology used to describe the trial designs is inconsistent, restricting the ability to identify these trials in the literature. By adopting the definitions and terminology presented in this article, the reporting of partially clustered trials can be substantially improved, and we present several recommendations for reporting these trial designs in practice. Greater awareness of partially clustered trials will facilitate more methodological research into their design and analysis, ultimately improving the quality of these trials.
- 10 January 2023
- Published by SAGE Publications in Clinical Trials
- Vol. 20 (2) , 99-110
Open AccessPartially clustered designs for clinical trials: Unifying existing designs using consistent terminology
Introduction: Clinical trial designs based on the assumption of independent observations are well established. Clustered clinical trial designs, where all observational units belong to a cluster and outcomes within clusters are expected to be correlated, have also received considerable attention. However, many clinical trials involve partially clustered data, where only some observational units belong to a cluster. Examples of such trials occur in neonatology, where participants include infants from both singleton and multiple births, and ophthalmology, where one or two eyes per participant may need treatment. Partial clustering can also arise in trials of group-based treatments (e.g. group education or counselling sessions) or treatments administered individually by a discrete number of health care professionals (e.g. surgeons or physical therapists), when this is compared to an unclustered control arm. Trials involving partially clustered data have received limited attention in the literature and the current lack of standardised terminology may be hampering the development and dissemination of methods for designing and analysing these trials. Methods and examples: In this article, we present an overarching definition of partially clustered trials, bringing together several existing trial designs including those for group-based treatments, clustering due to facilitator effects and the re-randomisation design. We define and describe four types of partially clustered trial designs, characterised by whether the clustering occurs pre-randomisation or post-randomisation and, in the case of pre-randomisation clustering, by the method of randomisation that is used for the clustered observations (individual randomisation, cluster randomisation or balanced randomisation within clusters). Real life examples are provided to highlight the occurrence of partially clustered trials across a variety of fields. To assess how partially clustered trials are currently reported, we review published reports of partially clustered trials. Discussion: Our findings demonstrate that the description of these trials is often incomplete and the terminology used to describe the trial designs is inconsistent, restricting the ability to identify these trials in the literature. By adopting the definitions and terminology presented in this article, the reporting of partially clustered trials can be substantially improved, and we present several recommendations for reporting these trial designs in practice. Greater awareness of partially clustered trials will facilitate more methodological research into their design and analysis, ultimately improving the quality of these trials.
- Open Access
Comparative Effects of Co-Ingesting Whey Protein and Glucose Alone and Combined on Blood Glucose, Plasma Insulin and Glucagon Concentrations in Younger and Older Men
The ingestion of dietary protein with, or before, carbohydrate may be a useful strategy to reduce postprandial hyperglycemia, but its effect in older people, who have an increased predisposition for type 2 diabetes, has not been clarified. Blood glucose, plasma insulin and glucagon concentrations were measured for 180 min following a drink containing either glucose (120 kcal), whey-protein (120 kcal), whey-protein plus glucose (240 kcal) or control (~2 kcal) in healthy younger (n = 10, 29 ± 2 years; 26.1 ± 0.4 kg/m2) and older men (n = 10, 78 ± 2 years; 27.3 ± 1.4 kg/m2). Mixed model analysis was used. In both age groups the co-ingestion of protein with glucose (i) markedly reduced the increase in blood glucose concentrations following glucose ingestion alone (p < 0.001) and (ii) had a synergistic effect on the increase in insulin concentrations (p = 0.002). Peak insulin concentrations after protein were unaffected by ageing, whereas insulin levels after glucose were lower in older than younger men (p < 0.05) and peak insulin concentrations were higher after glucose than protein in younger (p < 0.001) but not older men. Glucagon concentrations were unaffected by age. We conclude that the ability of whey-protein to reduce carbohydrate-induced postprandial hyperglycemia is retained in older men and that protein supplementation may be a useful strategy in the prevention and management of type 2 diabetes in older people.
Open AccessComparative Effects of Co-Ingesting Whey Protein and Glucose Alone and Combined on Blood Glucose, Plasma Insulin and Glucagon Concentrations in Younger and Older Men
The ingestion of dietary protein with, or before, carbohydrate may be a useful strategy to reduce postprandial hyperglycemia, but its effect in older people, who have an increased predisposition for type 2 diabetes, has not been clarified. Blood glucose, plasma insulin and glucagon concentrations were measured for 180 min following a drink containing either glucose (120 kcal), whey-protein (120 kcal), whey-protein plus glucose (240 kcal) or control (~2 kcal) in healthy younger (n = 10, 29 ± 2 years; 26.1 ± 0.4 kg/m2) and older men (n = 10, 78 ± 2 years; 27.3 ± 1.4 kg/m2). Mixed model analysis was used. In both age groups the co-ingestion of protein with glucose (i) markedly reduced the increase in blood glucose concentrations following glucose ingestion alone (p < 0.001) and (ii) had a synergistic effect on the increase in insulin concentrations (p = 0.002). Peak insulin concentrations after protein were unaffected by ageing, whereas insulin levels after glucose were lower in older than younger men (p < 0.05) and peak insulin concentrations were higher after glucose than protein in younger (p < 0.001) but not older men. Glucagon concentrations were unaffected by age. We conclude that the ability of whey-protein to reduce carbohydrate-induced postprandial hyperglycemia is retained in older men and that protein supplementation may be a useful strategy in the prevention and management of type 2 diabetes in older people.